###begin article-title 0
Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms
###end article-title 0
###begin p 1
Both authors contributed equally to this work.
###end p 1
###begin p 2
Joint senior authors.
###end p 2
###begin p 3
###xml 265 268 265 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 357 360 357 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 786 793 786 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 918 921 918 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 935 938 935 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1353 1358 <span type="species:ncbi:10090">mouse</span>
Vascular endothelial growth factor (VEGF) is produced either as a pro-angiogenic or anti-angiogenic protein depending upon splice site choice in the terminal, eighth exon. Proximal splice site selection (PSS) in exon 8 generates pro-angiogenic isoforms such as VEGF165, and distal splice site selection (DSS) results in anti-angiogenic isoforms such as VEGF165b. Cellular decisions on splice site selection depend upon the activity of RNA-binding splice factors, such as ASF/SF2, which have previously been shown to regulate VEGF splice site choice. To determine the mechanism by which the pro-angiogenic splice site choice is mediated, we investigated the effect of inhibition of ASF/SF2 phosphorylation by SR protein kinases (SRPK1/2) on splice site choice in epithelial cells and in in vivo angiogenesis models. Epithelial cells treated with insulin-like growth factor-1 (IGF-1) increased PSS and produced more VEGF165 and less VEGF165b. This down-regulation of DSS and increased PSS was blocked by protein kinase C inhibition and SRPK1/2 inhibition. IGF-1 treatment resulted in nuclear localization of ASF/SF2, which was blocked by SPRK1/2 inhibition. Pull-down assay and RNA immunoprecipitation using VEGF mRNA sequences identified an 11-nucleotide sequence required for ASF/SF2 binding. Injection of an SRPK1/2 inhibitor reduced angiogenesis in a mouse model of retinal neovascularization, suggesting that regulation of alternative splicing could be a potential therapeutic strategy in angiogenic pathologies.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fn" rid="FN4"><sup>5</sup></xref>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 526 529 526 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 615 616 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 647 650 647 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 909 915 909 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 915 916 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 959 962 959 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1061 1064 1061 1064 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1081 1082 1081 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1148 1149 1148 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1279 1280 1279 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1300 1301 1300 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1409 1410 1409 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1420 1421 1420 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1434 1436 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1446 1447 1446 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1468 1470 1468 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1502 1504 1502 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1681 1683 1681 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1698 1700 1698 1700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1884 1886 1884 1886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
Vascular endothelial growth factor (VEGF-A, hereafter referred to as VEGF)5 is a key regulatory component in physiological and pathological angiogenesis. Inhibition of VEGF has shown to be effective in cancer (1) and ocular angiogenesis (2), and it is up-regulated by a number of growth factors also implicated in these conditions, including insulin-like growth factor-1 (IGF-1) (3). VEGF is generated as multiple isoforms by alternative splicing (4). There are two principal families of VEGF isoforms, the pro-angiogenic VEGFxxx isoforms, generated by proximal splice site selection in the terminal exon, exon 8a (5), and the anti-angiogenic VEGFxxxb isoforms (6), generated by use of a distal splice site 66 bp further into exon 8, generating mRNA isoforms that contain exon 8b. As the stop codon for the protein is encoded in exon 8, these two isoforms contain alternate six amino acids at the C terminus (Fig. 1A). The pro-angiogenic isoforms such as VEGF165 encode a terminal six amino acid sequence of CDKPRR, and the anti-angiogenic isoforms such as VEGF165b encode SLTRKD (7). Many normal tissues, including the eye generate both isoforms (8), and previous studies have shown that the anti-angiogenic isoforms dominate in non-angiogenic tissues such as the normal colon (9) and the vitreous (8). However, there is a splicing switch in angiogenic conditions such as proliferative diabetic retinopathy (8), colon (9), prostate (10), renal (7), and skin cancers (11), and in Denys Drash Syndrome (12). In contrast, in non-angiogenic conditions where VEGF is up-regulated, such as glaucoma and rhegmatogenous retinal detachment associated with proliferative vitreoretinopathy (13) or glaucoma (14), the anti-angiogenic isoforms are up-regulated. We have previously shown that IGF-1 can switch splicing in cultured epithelial cells from anti-angiogenic to pro-angiogenic isoforms (15). As IGF-1 has been implicated in a number of angiogenic conditions including diabetic retinopathy and colon cancer, we hypothesized that the mechanism through which IGF-1 mediates this change in splicing may be a potential therapeutic target to prevent angiogenesis. To this end, we have investigated the signaling pathways, the splicing factors involved, and the possibility of therapeutic intervention in the pathway in an animal model of diabetic retinopathy.
###end p 5
###begin p 6
###xml 62 65 62 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Inhibition of PKC by BIM1 prevents the down-regulation of VEGF<sub>xxx</sub>b by IGF.</bold>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 192 195 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSS</italic>
###xml 221 224 221 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DSS</italic>
###xml 480 502 480 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">horizontal arrows. B&#8211;D</italic>
###xml 544 545 543 544 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 588 589 587 588 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 592 593 591 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 635 638 634 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 643 646 642 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 672 673 671 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 762 765 761 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 800 801 799 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 905 908 904 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 960 963 959 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 970 971 969 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Inhibition of PKC by BIM1 prevents the down-regulation of VEGFxxxb by IGF.A, exon structure of the VEGF pre-mRNA. Alternative splicing of exon 8 to either 8a or 8b results in use of proximal (PSS) or distal splice sites (DSS) resulting in shorter mRNA for distal splicing. Because the last stop codon is missing, the final six amino acid open reading frame is replaced by an identically sized open reading frame encoding six different amino acids. The primer position is shown by horizontal arrows. B-D, podocytes were treated with BIM1 (2.5 mum) alone or in combination with IGF-1 (100 nm). B, RT-PCR showed that BIM1 reduced the VEGFxxx:VEGFxxxb ratio at the RNA level. C, Western blot demonstrating that BIM1 inhibited the IGF-mediated down-regulation of VEGFxxxb expression at the protein level. D, ELISA results confirming that BIM1 specifically attenuated the IGF-1-dependent down-regulation of VEGFxxxb, but does not affect endogenous expression of VEGFxxxb. **, p < 0.01 compared with untreated.
###end p 6
###begin title 7
EXPERIMENTAL PROCEDURES
###end title 7
###begin title 8

###end title 8
###begin title 9

###end title 9
###begin title 10
Proliferating Podocytes
###end title 10
###begin p 11
###xml 342 344 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 619 620 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 434 440 <span type="species:ncbi:9913">bovine</span>
PCIPs (courtesy of Moin Saleem, University of Bristol, Bristol, UK) were derived from a cell line conditionally transformed from normal human podocytes with a temperature-sensitive mutant of immortalized SV-40 T-antigen. At the permissive temperature of 33 degreesC, the SV-40 T-antigen is active and allows the cells to proliferate rapidly (16). PCIPs were cultured in T75 flasks (Greiner) in RPMI 1640 medium (Sigma) with 10% fetal bovine serum, 1% ITS (insulin transferrin selenium) (Sigma), 0.5% penicillin-streptomycin solution (Sigma), and grown to 95% confluency. Then cells were split into 6-well plates (2 x 105 cells per well) and grown until 95% confluency.
###end p 11
###begin title 12
Treatments with IGF-1 and Pharmacological Inhibitors
###end title 12
###begin p 13
###xml 53 56 53 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 572 573 571 572 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 611 612 609 610 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
To investigate the inhibitory effect of IGF-1 on VEGFxxxb mRNA and protein synthesis, pharmacological inhibitors and IGF-1 with PKC-BIMI (Calbiochem), and SRPK1/2 (SR protein kinases 1 and 2)-SRPIN340 (SR protein phosphorylation inhibitor 340) (17) were used. 24 h before treatment, cultured medium was replaced with serum-free RPMI 1640 medium (Sigma) containing 1% ITS (Sigma) and 0.5% penicillin-streptomycin (Sigma). Subsequently, the medium was replaced with fresh serum-free RPMI 1640 medium (Sigma) containing 1% ITS, 0.5% penicillin-streptomycin, and either 2.5 mum BIMI (bisindolylmaleimide 1) or 10 mum SRPIN340 for 60 min before treatment with IGF-1. 12 h after stimulation, RNA was extracted, and 48 h after stimulation, proteins were extracted.
###end p 13
###begin title 14
RT-PCR
###end title 14
###begin p 15
###xml 105 107 104 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15</sub>
###xml 383 384 369 370 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 846 849 813 816 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 882 885 849 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 1244 1245 1209 1210 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1214 1217 <span type="species:ncbi:9685">cat</span>
1 mug of mRNA was reverse transcribed using MMLV RT, RNase H Minus, point mutant (Promega), and oligo(dT)15 (Promega) as a primer. The reaction was carried out in Bio-Rad cycler for 60 min at 40 degreesC, and then the enzyme was inactivated at 70 degreesC for 15 min. Ten percent of the cDNA was then amplified using primers designed to pick up proximal and distal splice forms. 1 mum of each primer (exon 7b 5'-GGCAGCTTGAGTTAAACGAAC-3', exon 8b 5'-ATGGATCCGTATCAGTCTTTCCTGG-3') and PCR Master Mix (Promega) were used in reactions cycled 30 times, denaturing at 95 degreesC for 60 s, annealing at 55 degreesC for 60 s, and extending at 72 degreesC for 60 s. PCR products were run on 2.5% agarose gels containing 0.5 mug/ml ethidium bromide and visualized under a UV transilluminator. This reaction usually resulted in one amplicon of 130 bp (VEGFxxx) and one amplicon of 64 bp (VEGFxxxb). For HEK293 and HeLa cells, RT-PCR was performed using primers specific to exon 7a and the 3'-untranslated region of the VEGF mRNA. The primers used were 5'-GTAAGCTTGTACAAGATCCGCAGACG-3' and 5'-ATGGATCCGTATCAGTCTTTCCTGG-3'. The reaction was set up in a 20-mul reaction using the 2x FastStart Universal SyBR Master Mix (Roche, cat. no: 04913850001) and 1 mum each primer. The reaction was performed on the ABI 7000 cycler for 95 degreesC for 10 min, followed by 30 cycles of 95 degreesC for 15 s and 55 degreesC for 30 s.
###end p 15
###begin title 16
Western Blotting
###end title 16
###begin p 17
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 371 374 363 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 586 589 575 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 664 667 653 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 694 697 683 686 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 749 752 738 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 759 762 748 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 773 776 762 765 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 803 806 792 795 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 836 839 825 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 907 910 896 899 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 913 914 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1142 1145 1131 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 975 986 <span type="species:ncbi:3704">horseradish</span>
Protein samples were dissolved in Laemmli buffer, boiled for 3-4 min, and centrifuged for 2 min at 20,000 x g to remove insoluble materials. 30 mug of protein per lane were separated by SDS/PAGE (12%) and transferred to a 0.2-mum nitrocellulose membrane. The blocked membranes were probed overnight (4 degreesC) with antibodies against panVEGF (R&D; MAB 293, 1:500), VEGFxxxb (R&D Systems; MAB3045; 1:250), ASF/SF2 antibody (Santa Cruz Biotechnology; sc-10254; 1:1000), and beta-tubulin (Sigma, 1:2000). Western blotting has previously shown that all the proteins recognized by the VEGFxxxb antibody are also recognized by commercial antibodies raised against VEGF165. It binds recombinant VEGF165b, and can be used to demonstrate expression of VEGF165b, VEGF189b, and VEGF121b (collectively termed VEGFxxxb) but does not recognize VEGF165, conclusively demonstrating that this antibody is specific for VEGFxxxb (6). Subsequently, the membranes were incubated with secondary horseradish peroxidase-conjugated antibody, and immunoreactive bands were visualized using ECL reagent (Pierce). Immunoreactive bands corresponding to panVEGF and VEGFxxxb in each treatment were quantified by ImageJ analysis and normalized to those of beta-tubulin or beta-actin. Blots are representative of at least three experiments. Densitometry was carried out by scanning in gels and using ImageJ to determine gray levels of bands and background.
###end p 17
###begin title 18
Construction of Plasmids
###end title 18
###begin p 19
###xml 161 162 160 161 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 184 191 183 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 198 199 197 198 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
The VEGF sequence of interest (from 35-bp upstream of exon 8a to 35-bp downstream of exon 8b) was amplified from a BAC DNA template using 50 ng of BAC DNA, 10 mum of each primers (see Table 1), 10 mm dNTP mix (Promega), and Taq polymerase (Promega). A modified ADML-MS2 plasmid was digested with EcoR1 and BamH1, and PCR products ligated into the vector and subsequently transformed. Colonies were selected, and plasmid extraction (Qiagen) was performed. The identities of the plasmids were confirmed by sequencing.
###end p 19
###begin p 20
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Primer sequences</bold>
Primer sequences
###end p 20
###begin title 21
Expression of the MS2-MBP (Maltose-binding Protein) Fusion Protein
###end title 21
###begin p 22
###xml 70 86 70 86 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Escherichia coli</named-content>
###xml 215 216 199 200 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 239 240 220 221 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 405 406 386 387 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 70 86 <span type="species:ncbi:562">Escherichia coli</span>
###xml 663 669 <span type="species:ncbi:9986">rabbit</span>
MS2-MBP (a gift from Robin Reed, Harvard University) was expressed in Escherichia coli DH5alpha. The cells were grown to an optical density of approximately0.5 at 600 nm and induced for expression for 3 h with 0.2 mm isopropyl-1-thio-beta-d-galactopyranoside. The MS2-MBP protein was purified by amylose beads according to the manufacturer's protocol (NEB, Beverly, MA). The protein was dialyzed with 10 mm sodium phosphate, pH 7, overnight at 4 degreesC, to remove existing salts that are present and further purified over a Heparin Hi Trap column using a NaCl gradient (GE Healthcare). An immunoblot analysis was performed on the purified fusion proteins using rabbit anti-MS2 antibody (gift from Peter Stockley, Leeds University) to confirm the identity of the protein.
###end p 22
###begin title 23
Assembly of the MS2-MBP System
###end title 23
###begin p 24
###xml 62 67 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vitro</italic>
###xml 117 118 116 117 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 138 139 137 138 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 153 154 152 153 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 159 160 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 166 167 165 166 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 187 188 186 187 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 354 355 347 348 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 378 379 371 372 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 498 499 491 492 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 510 511 503 504 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 516 517 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 523 524 516 517 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 718 719 699 700 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 733 734 714 715 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 753 754 734 735 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 765 766 746 747 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 796 797 774 775 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
1 mug of the VEGF-MS2 plasmid was linearized with Xba1 and in vitro transcribed with T7 RNA polymerase (NEB) in 0.5 mm rNTP (Ambion), 40 mm Tris-HCl, 6 mm MgCl2, 10 mm dithiothreitol, 2 mm spermidine at 40 degreesC for 1 h to make VEGF-MS2 RNA. A 100-fold molar excess of MS2-MBP fusion protein and VEGF-MS2 RNA were incubated in a buffer containing 20 mm HEPES, pH 7.9 and 60 mm NaCl on ice for 30 min. 75 mg of HEK293 nuclear extract were added to the MS2-MBP fusion protein/VEGF-RNA mix in 0.5 mm ATP, 6.4 mm MgCl2, 20 mm creatine phosphate for 1 h at 30 degreesC. Proteins that bound to the MS2-MBP/VEGF-MS2 RNA complex were affinity selected on amylose beads by rotating for 4 h at 4 degreesC and eluted with 12 mm maltose, 20 mm HEPES pH 7.9, 60 mm NaCl, 10 mm beta-mercaptoethanol, and 1 mm phenylmethylsulfonyl fluoride.
###end p 24
###begin title 25
RNA Immunoprecipitation
###end title 25
###begin p 26
###xml 560 561 554 555 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 691 692 684 685 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 716 717 709 710 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 727 728 720 721 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1546 1547 1539 1540 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1567 1568 1560 1561 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1578 1579 1571 1572 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1641 1642 1634 1635 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1747 1748 1734 1735 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1769 1770 1756 1757 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1781 1782 1768 1769 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2173 2175 2148 2150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15</sub>
###xml 140 143 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1141 1147 <span type="species:ncbi:9913">bovine</span>
###xml 1211 1216 <span type="species:ncbi:10090">mouse</span>
HEK293 cells were transfected with plasmid containing the last 131 nt of intron 7 and the first 152 nt of exon 8 inserted downstream of the CMV promoter in pTARGET. Two variants of this were generated by site-directed mutagenesis: a deletion of 11 nucleotides upstream of the PSS from -4 to -24 nt, and the second is a mutation of the sequence CTTTGTTTTCCATTTC to GGGGGGGGGGCAGGGG. Cells were cross-linked for 10 min at 4 degreesC with 1% formaldehyde in phosphate-buffered saline and blocked by the addition of glycine, pH 8, at a final concentration of 250 mm. The cells were washed twice with PBS, and the cell pellet resuspended in 500 mul of radioimmune precipitation assay buffer (50 mm, Tris-Cl, pH 7.5, 150 mm NaCl, 1 mm EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.05% SDS) and incubated on ice for 20 min. The cells were sonicated three times for 15 s with an XL ultrasonic homogenizer (setting 5) and incubated on ice for 2 min between each sonication. The extract was centrifuged for 10 min at 10,000 rpm and precleared by a 1-h incubation at room temperature with protein A-agarose beads (previously coated with 0.5 mg/ml bovine serum albumin and 0.2 mg/ml herring sperm DNA). The antibodies mouse IgG (vector I-200) or anti-ASF/SF2 (SC96, Santa Cruz Biotechnology) were incubated for 1 h at room temperature with protein A-agarose beads (Sigma, coated as above). ASF/SF2-containing complexes were pulled down after a 2-h incubation of the precleared extract with the antibody/beads and washed six times for 10 min each in 50 mm Tris-Cl, pH 7.5, 1 m NaCl, 1 mm EDTA, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1.5 m urea. The complexes were eluted and cross-link reversed by treatment for 45 min at 70 degreesC with 50 mm Tris-Cl, pH 7.5, 5 mm EDTA, 10 mm dithiothreitol, and 1% SDS. RNA was then extracted with Tri-reagent solution (Ambion) according to the manufacturer's protocol, precipitated with 0.8 volumes of isopropyl alcohol in the presence of glycoblue (Ambion), the pellet resuspended in water, and subjected to DNase treatment for 1 h at 37 degreesC and reverse transcription for 1 h at 42 degreesC using MMLV (Promega) and oligo(dT)15. PCR was carried out using the Master Mix from Promega and specific primers for the plasmid VEGF sequence. 5'-CTAGCCTCGAGACGCGTGAT-3' and 5'-GGCAGCGTGGTTTCTGTATC-3' or GAPDH.
###end p 26
###begin title 27
Oxygen-induced Retinopathy (OIR)
###end title 27
###begin p 28
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 785 786 777 778 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 791 792 783 784 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 799 800 791 792 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 805 807 797 799 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2,</sub>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 660 666 <span type="species:ncbi:9913">bovine</span>
The OIR model was performed as previously described (18, 19) with minor modifications. Neonatal C57/Bl6 mice and nursing CD1 dams were exposed to 75% oxygen between P7 and P12. Return to room air induced hypoxia in the ischemic areas. On P13, mice received either HBSS or SRPIN340 (10 pmol) in Hank's-buffered solution in a 1-mul intraocular injections using a Nanofil syringe fitted with a 35-gauge needle (WPI, Sarasota, FL) into the left eye under isoflurane anesthesia. On P17, both eyes were dissected, fixed in 4% paraformaldehyde overnight at 4 degreesC, and retinas were dissected. Retinas were permeabilized in PBS containing 0.5% Triton X-100 and 1% bovine serum albumin, stained with 20 mug/ml biotinylated isolectin B4 (Sigma Aldrich) in PBS, pH 6.8, 1% Triton X-100, 0.1 mm CaCl2, 0.1 mm MgCl2, followed by 20 mug/ml ALEXA 488-streptavidin (Molecular Probes, Eugene, OR) and flat mounted in Vectashield (Vector Laboratories, Burlingame, CA). Retinas were examined under a Nikon Eclipse 400 epifluorescence microscope and areas of neovascularization identified under a 4x objective. Images were captured and imported into Image J, and neovascular, ischemic, and normal areas were traced and measured. Imaging was done by investigator, blinded to treatment.
###end p 28
###begin title 29
###xml 17 22 <span type="species:ncbi:10090">Mouse</span>
Real-time PCR on Mouse OIR Retina
###end title 29
###begin p 30
###xml 107 108 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 391 393 389 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15</sub>
###xml 530 531 528 529 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 557 560 555 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
HBSS or 100 pmol of SRPIN340 in 1 mul was injected intraocularly into OIR pups on day 13 (day 7-12 in 75% O2), and after 48 h, the eyes were enucleated and placed in RNAlater (Sigma Aldrich), and the retinae were excised. Total RNA was extracted using RNAeasy (Qiagen) according to the manufacturer's manual, and 0.3 mug of DNase-digested total RNA was reverse transcribed using the oligo(dT15) primer. Real-time PCR was performed on a Cepheid Real time thermocycler using ABsolute QPCR SYBR green mix (Thermo Scientific) and 70 nm primers specific for VEGF165 (exon 7/8a) or total VEGF (exon 2/3) at 95 degreesC for 15 min, then 95 degreesC for 15 s, and 60 degreesC for 30 s x 40 cycles or for the housekeeping gene (beta-actin) 95 degreesC 15 min, at 95 degreesC for 15 s, 55 degreesC for 30 s, 72 degreesC for 30 s x 40 cycles.
###end p 30
###begin title 31
Immunocytofluorescence
###end title 31
###begin p 32
###xml 119 124 <span type="species:ncbi:9796">horse</span>
###xml 248 252 <span type="species:ncbi:9925">goat</span>
###xml 285 291 <span type="species:ncbi:9793">donkey</span>
###xml 297 301 <span type="species:ncbi:9925">goat</span>
Cells were washed with PBS, fixed for 5 min with 4% (w/v) PFA, washed with PBS in 0.05% Triton X (PBS-T) blocked in 5% horse serum in PBS-T (1 h), washed three times, and incubated overnight with 2 mug/ml of anti-ASF/SF2 (SC10255) or a nonspecific goat IgG, washed, and incubated with donkey anti-goat Alexa Fluor 594 for visualization and counterstained for the nucleus with Hoechst. Images were taken at 40x magnification with the Nikon Eclipse 400 epifluorescence microscope or 60x on a Perkin Elmer Ultraview-Fret H confocal microscopy system.
###end p 32
###begin title 33
Statistical Analysis
###end title 33
###begin p 34
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 221 222 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Statistical analyses were carried out on raw data using the Friedman test (Dunnet post-test), and a p value of less than 0.05 was considered statistically significant. Values are expressed as means +/- S.E. For all data, n represents the number of independent cell populations or derived from different donors.
###end p 34
###begin title 35
RESULTS
###end title 35
###begin title 36

###end title 36
###begin title 37

###end title 37
###begin title 38
The IGF-1-dependent Switch between Isoforms Is PKC-dependent
###end title 38
###begin p 39
###xml 184 185 184 185 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 202 203 201 202 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 312 315 311 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 366 369 365 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 470 473 469 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 498 501 497 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 553 554 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 563 569 558 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 569 570 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 593 594 588 589 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 611 612 605 606 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 656 659 650 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 664 667 658 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 759 760 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 838 839 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 848 854 836 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 854 855 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
To determine whether the IGF-1-mediated switch in splicing was regulated by PKC inhibition, podocytes were incubated with pharmacological inhibitors of PKC (BIMI). Treatment with 100 nm IGF-1 and 2.5 mum BIMI, the PKC inhibitor, followed by RNA extraction and RT-PCR using primers that detect both proximal (VEGFxxx, 130-bp amplicon) and distal splice isoforms (VEGFxxxb, 64 bp amplicon) was carried out. Treatment with IGF-1 increased the relative intensity of the VEGFxxx (upper) band to the VEGFxxxb band (lower) from 1.39 +/- 0.42 to 4.84 +/- 0.65 (p < 0.01, Fig. 1B). Treatment with 100 nm IGF-1 and 2.5 mum BIMI, the PKC inhibitor, resulted in a VEGFxxx:VEGFxxxb density of 2.12 +/- 0.39, which was lower than treatment with IGF-1 alone (4.84 +/- 0.65, p < 0.05) but was not different from treatment with BIMI alone (1.62 +/- 0.76, p > 0.05, Fig. 1B).
###end p 39
###begin p 40
###xml 253 254 253 254 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 271 272 270 271 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 354 357 350 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 451 452 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 538 539 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 548 554 538 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 554 555 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 594 600 584 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 600 601 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
To determine whether IGF-1-mediated regulation of splicing was apparent at the protein level, podocytes were incubated with the pharmacological inhibitors of PKC (BIMI), and ELISA carried out on the protein extracted from the cells. Treatment with 100 nm IGF-1 and 2.5 mum BIMI, the PKC inhibitor, resulted in cells producing 0.47 +/- 0.03 pg/mug of VEGFxxxb, which was significantly greater than cells treated with IGF-1 alone (0.12 +/- 0.02 pg/mug, p < 0.001) but was not different from treatment with BIMI alone (0.40 +/- 0.06 pg/mug, p > 0.05, Fig. 1D). This was confirmed by Western blot (Fig. 1C).
###end p 40
###begin title 41
PKC Activation Induces Proximal Splice Site Selection
###end title 41
###begin p 42
###xml 125 126 125 126 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 322 325 322 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 339 345 339 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 475 478 475 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 517 523 517 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 523 524 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 574 577 574 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 587 593 587 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 593 594 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
To determine whether the PKC activation was sufficient to cause proximal splice site selection, cells were treated with 100 nm phorbol myristate acetate (PMA), which is known to induce PKC activation. PMA treatment resulted in a significant increase in VEGF expression as determined by Western blot, but a decrease in VEGF165b expression (Fig. 2A). To confirm this quantitatively, ELISA was performed on protein extracted from these cells, and a significant reduction in VEGF165b but increase in total VEGF was seen (Fig. 2B). This results in a decrease in the relative VEGFxxxb levels (Fig. 2C).
###end p 42
###begin p 43
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Proximal splicing is activated by protein kinase C.</bold>
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</italic>
###xml 118 121 118 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
Proximal splicing is activated by protein kinase C.A-C, treatment of podocytes with the PKC activator PMA reduced VEGF165b expression, but increased expression of total VEGF as measured by Western blot (A) and ELISA (B). This results in a change of relative expression from 60% (anti-angiogenic) to just under 50% (angiogenic) (C).
###end p 43
###begin title 44
###xml 55 58 55 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
SRPK1/2 Inhibition Prevents the Down-regulation of VEGFxxxb by IGF-1
###end title 44
###begin p 45
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 230 233 230 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 305 306 304 305 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 355 356 354 355 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 434 435 432 433 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 495 498 493 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 503 506 501 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 598 599 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 681 682 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 691 697 683 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 697 698 689 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 781 784 773 776 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 837 838 823 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 986 989 969 972 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 1014 1015 994 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1025 1031 1005 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1031 1032 1011 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1077 1083 1057 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1083 1084 1063 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1258 1264 1238 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1264 1265 1244 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1502 1505 1482 1485 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1529 1532 1509 1512 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1589 1592 1569 1572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
There are a number of splicing factor kinases that are activated by PKC, including the SR protein kinases SRPK1 and SRPK2 (20, 21). To test the effect of SRPIN340, an inhibitor of SRPK1/2, on IGF-1-mediated down-regulation of VEGFxxxb at the protein and mRNA level, cells were treated with SRPIN340 (10 mum) alone and then in combination with IGF-1 (100 nm). Amplification of cDNA from podocytes showed that IGF-1 treatment with 10 mum SRPIN340, the SRPK1/2 inhibitor resulted in a relative VEGFxxx:VEGFxxxb density of 1.26 +/- 0.22, which was lower than treatment with IGF-1 alone (4.84 +/- 0.65, p < 0.01) but was not different from treatment with SRPIN340 alone (1.45 +/- 0.30, p > 0.05, Fig. 3A). At the protein level, SRPIN340 inhibited IGF-1-dependent down-regulation of VEGFxxxb from 0.12 +/- 0.02 pg/mug to 0.50 +/- 0.05 pg/mug (p < 0.001), but not when SRPIN340 was used alone (0.45 +/- 0.01 pg/mug), indicating that SRPK inhibition did not affect endogenous expression of VEGFxxxb (0.42 +/- 0.02 pg/mug, p > 0.05) (Fig. 3C). This was again confirmed by Western blot (Fig. 3B). To confirm the involvement of SRPK1 or SRPK2 in the terminal splice site choice, epithelial cells were transfected with expression vectors to overexpress SRPK1 and SRPK2. Fig. 3D shows that overexpression of SRPK1, but not SRPK2, resulted in reduced distal splice site selection and hence reduced overall VEGF levels. By itself, it was not sufficient to simply switch the splicing but resulted in inhibition of VEGF165b without increased VEGF165. Interestingly, SRPK2 overexpression did not affect VEGF165b production, although it did reduce total VEGF expression.
###end p 45
###begin p 46
###xml 70 73 70 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Inhibition of SPRK1/2 by SRPIN340 prevents the down-regulation of VEGF<sub>xxx</sub>b by IGF.</bold>
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;D</italic>
###xml 126 127 125 126 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 170 171 169 170 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 174 175 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 221 224 220 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 229 232 228 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 258 259 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 352 355 351 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 390 391 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 499 502 498 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 553 556 552 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 559 560 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 633 636 632 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 732 735 731 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
Inhibition of SPRK1/2 by SRPIN340 prevents the down-regulation of VEGFxxxb by IGF.A-D, cells were treated with SRPIN340 (10 mum) alone or in combination with IGF-1 (100 nm). A, RT-PCR showed that SRPIN340 reduced the VEGF165:VEGF165b ratio at the RNA level. B, Western blot demonstrating that SRPIN340 inhibited the IGF-mediated down-regulation of VEGFxxxb expression at the protein level. C, ELISA results confirming that SPRIN340 specifically attenuates the IGF-1-dependent down-regulation of VEGFxxxb, but did not affect endogenous expression of VEGFxxxb. D, ELISA of the protein extract shows that SRPK1 transfection reduces VEGFxxxb expression, and total VEGF expression. SRPK2 reduces total expression, but did not affect VEGFxxxb expression.
###end p 46
###begin title 47
IGF1 Treatment Resulted in Nuclear Localization of ASF/SF2, which Was Blocked by SPRK1/2 Inhibition
###end title 47
###begin p 48
###xml 209 210 209 210 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 257 263 257 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 397 403 397 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 452 458 452 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 460 470 460 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B versus D</italic>
###xml 819 825 819 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 827 828 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 833 834 833 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 1427 1430 1427 1430 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1484 1490 1484 1490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 1490 1491 1490 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1552 1555 1552 1555 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1612 1615 1612 1615 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1703 1706 1703 1706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
SRPK1 has been shown to phosphorylate ASF/SF2, which we have previously shown to favor proximal splice site selection. To determine whether IGF-1 altered ASF/SF2 localization, podocytes were treated with 100 nm IGF and stained for ASF/SF2. Untreated cells (Fig. 4A) contained both nuclear and cytoplasmic ASF/SF2, whereas after treatment with IGF-1, ASF/SF2 localized specifically to the nucleus (Fig. 4B). This localization was inhibited by SRPIN340 (Fig. 4, B versus D), indicating that IGF1-mediated activation of SRPK1/2 was responsible for the nuclear localization of ASF/SF2. It has previously been demonstrated that ASF/SF2 can be shuttled from the nucleus to the cytoplasm in HeLa cells, but is predominantly nuclear. We therefore investigated ASF/SF2 localization in these and another cell type, HEK293 cells. Fig. 4, E and F shows that whereas in HEK293 cells there is a strong cytoplasmic localization for the ASF/SF2, in HeLa cells expression is predominantly nuclear, as previously described. This subcellular localization of ASF/SF2 was confirmed by the use of a second ASF/SF2 antibody. Furthermore, high resolution gel electrophoresis showed that whereas podocyte cytoplasmic protein contains a single molecular weight ASF/SF2, an additional higher molecular weight band is seen in podocyte nuclei (data not shown), confirming that in podocytes ASF/SF2 is both cytoplasmic and nuclear. We also investigated VEGF165b mRNA expression in these two additional cell types. Fig. 4G shows that HEK cells (with cytoplasmic ASF/SF2) express VEGF165b, whereas HeLa cells (nuclear ASF/SF2) only express VEGF165. This is consistent with the cytoplasmic location of ASF/SF2 being associated with VEGF165b expression.
###end p 48
###begin p 49
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nuclear localization of ASF/SF2 is increased by IGF-1.</bold>
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;F</italic>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 331 332 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 508 509 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 570 571 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 613 616 613 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 653 656 653 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MWM</italic>
Nuclear localization of ASF/SF2 is increased by IGF-1.A-F, cells were treated with vehicle or IGF in the presence or absence of SRPIN340 and stained for ASF/SF2 and counterstained with Hoechst. A, podocytes show expression of ASF/SF2 in the nucleus and in the cytoplasm. B, IGF induces nuclear localization of cytoplasmic ASF/SF2. C, SRPIN340 by itself does not affect localization of ASF/SF2. D, SRPIN340 inhibited this IGF-mediated localization. E, HEK cells also show cytoplasmic localization of ASF/SF2. F, in contrast, HeLa cells have nuclear ASF/SF2 localization. G, RT-PCR of mRNA from HEK cells shows VEGF165b expression, but not in HeLa cells. MWM, molecular weight marker.
###end p 49
###begin title 50
ASF/SF2 Requires a 35-nt Region around the Proximal Splice Site of Exon 8 to Bind to VEGF mRNA
###end title 50
###begin p 51
###xml 165 171 165 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1113 1119 1113 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 1119 1120 1119 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1276 1277 1275 1276 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1701 1707 1700 1706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 1707 1708 1706 1707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
To determine whether ASF/SF2 could bind directly to the proximal splice site RNA, we used the MS2-MBP system to pull-down proteins that could interact with the RNA. Fig. 5A shows that ASF/SF2 was present both in crude nuclear extract and in the pull-down of nuclear extract incubated with an RNA containing the MS2 binding domain RNA fused to an 88-nt fragment containing the initial 35 nucleotides upstream of exon 8a, the coding sequence of exon 8a, and 35 nucleotides of 3'-UTR. In contrast, less ASF/SF2 was seen in the pull-down of nuclear extract incubated with the mRNA that did not have the 35 nucleotides upstream of exon 8a and did not bind the MS2 binding domain by itself, indicating that ASF/SF2 required a 35-nt fragment of exon 8a upstream of the proximal splice site to most efficiently bind the VEGF pre-mRNA. To determine whether binding of ASF/SF2 was PKC-dependent and whether this was SRPK1-dependent, HEK293 cells were treated with the PKC activator PMA in the presence or absence of the SRPK inhibitor SRPIN340, and then the protein run on an MS2-MBP column with the VEGF exon 8 construct. Fig. 5B shows that in cells treated with PMA, more ASF/SF2 binds to the VEGF construct than in untreated cells. This increase was inhibited by treatment with 10 mum SRPIN340 or by treatment with the phosphatase PP1. The sequence 35 nucleotides upstream of the PSS contains ASF/SF2 and U2AF65 consensus binding sequences. To determine more precisely the sequence required for ASF/SF2 binding to the RNA, a short sequence upstream of the proximal splice site was mutated (14 nt) or deleted (11 nt) in a plasmid containing just the terminal part of intron 7 and the proximal part of exon 8. Fig. 5D shows that the three constructs express the recombinant VEGF RNA (total cell extract, TCE). However, only the wild-type RNA was pulled-down with the ASF/SF2 protein, suggesting that the region we have mutated or deleted is required for ASF/SF2 binding to the VEGF pre-mRNA.
###end p 51
###begin p 52
###xml 0 95 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ASF/SF2-1 binds a 35-nt region of VEGF pre-mRNA upstream of the proximal splice site of exon 8.</bold>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 320 331 320 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro. B</italic>
###xml 381 383 381 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NE</italic>
###xml 772 773 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 989 990 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1107 1110 1107 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">top</italic>
###xml 1147 1150 1147 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCE</italic>
###xml 1209 1212 1209 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IgG</italic>
###xml 1310 1321 1310 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bottom blot</italic>
###xml 1198 1203 <span type="species:ncbi:10090">mouse</span>
###xml 1226 1231 <span type="species:ncbi:10090">mouse</span>
###xml 1496 1501 <span type="species:ncbi:10090">mouse</span>
ASF/SF2-1 binds a 35-nt region of VEGF pre-mRNA upstream of the proximal splice site of exon 8.A, constructs were generated containing fragments of the exon 7/exon 8 boundary, fused to a sequence encoding the stem loop structures recognized by the MBP-MS2-binding protein, which can bind maltose. These were transcribed in vitro. B, Western blot of HEK cell crude nuclear extract (NE) or NE incubated with mRNA constructs as above and run over a maltose column to isolate proteins that bind to the RNA constructs and probed with an ASF/SF2 antibody. Whereas mRNA containing the 5' regions of the intron 7/exon 8 boundary contained ASF/SF2 immunoreactivity, RNA encoding the exon 8 region did not, identifying the binding site for ASF/SF2 in the intron 7/exon 8a boundary. C, immunoblot of HEK cell NE of cells treated as shown incubated with the RNA construct C and run over the MS2-MBP column. PMA activation increased binding, and this was blocked by SRPIN340 and phosphatase treatment. D, RNA immunoprecipitation of ASF/SF2 in cells expressing constructs with a mutated or deleted intron 7 sequence. The top shows RT-PCR of total cell extract (TCE) or immunoprecipitated RNA using a nonspecific mouse IgG (IgG), or using a mouse monoclonal antibody to ASF/SF2 using primers to detect the VEGF sequence. The bottom blot shows the same treatments subjected to GAPDH amplification. The wild-type sequence showed a stronger band in the ASF/SF2 IP, whereas the mutants showed no difference between mouse IgG and ASF/SF2.
###end p 52
###begin title 53
###xml 46 51 <span type="species:ncbi:10090">Mouse</span>
SRPK1/2 Inhibition Inhibits Angiogenesis in a Mouse Model of Retinal Neovascularization
###end title 53
###begin p 54
###xml 131 134 131 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 463 469 463 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 636 639 636 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 674 680 674 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 682 683 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 688 689 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 158 163 <span type="species:ncbi:10090">mouse</span>
###xml 325 330 <span type="species:ncbi:10090">mouse</span>
To determine whether the inhibition of proximal splice site selection by blocking SRPK1/2, and hence increased anti-angiogenic VEGF165b production, we used a mouse model of retinal neovascularization where angiogenesis is driven by hypoxia, a process known to favor proximal splice site selection. Injection of SRPIN340 into mouse retina resulted in a significant inhibition of neovascular area of the retina, as well as a significant reduction in ischemic area (Fig. 6, C, D, and F). This resulted in a significant increase in the normally vascularized area, a result that is qualitatively consistent with injection of recombinant VEGF165b into the vitreous in this model (Fig. 6, E and F). To determine whether VEGF levels were altered by SRPIN340 treatment, mRNA was extracted from the retinae and subjected to Q-PCR for all VEGF isoforms using primers in exon 2 and 3. Treatment of eyes with SRPIN340 made no difference in overall VEGF levels (2.3 +/- 0.5% of actin compared with 2.2 +/- 2.0%). However, exon 8a containing mRNA was altered from 1.1 +/- 0.5 to 0.3 +/- 0.2% of actin).
###end p 54
###begin p 55
###xml 0 98 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Neovascularization induced by hyperoxia is inhibited by a single dose of SRPK inhibitor, SRPIN340.</bold>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">white</italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">orange</italic>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 336 349 336 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">arrowheads. C</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 550 551 548 549 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 594 595 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 643 644 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 686 687 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 754 757 752 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Neo</italic>
###xml 771 775 769 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">isch</italic>
###xml 787 791 785 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Norm</italic>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
Neovascularization induced by hyperoxia is inhibited by a single dose of SRPK inhibitor, SRPIN340.A, low power fluorescence micrograph of FITC-labeled lectin staining of retinal whole mounts with areas of NV (white) and ischemic (orange) outlined. B, higher power view of a single retinal quadrant, with angiogenic areas highlighted by arrowheads. C, high power view of retinal angiogenic area showing sprouting endothelial cells. D, quantification of neovascular areas shows a small but significant inhibition by a single injection of 1 mul of 10 mum SRPIN340 1 day after removal from oxygen. E, ischemic area was also reduced in these mice. F, normal area was consequently increased. G, data shown as relative to control, uninjected contralateral eye. Neo, neovacular; isch, ischemia; Norm, normal.
###end p 55
###begin title 56
DISCUSSION
###end title 56
###begin p 57
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">&#8211;</xref>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
VEGF induction by IGF-1 occurs via different signaling pathways including PKC (22) and PI3-K (23-25). There is increasing evidence that transducing components that link the cell surface with the nuclear splicing machinery implicate signaling pathways such as PKC (26), PI3-K (27, 28), or PKB/Akt (29, 30). IGF-1 modulates splicing of VEGF isoforms by preferential use of the PSS to increase expression of pro-angiogenic isoforms (15). Moreover, previously we have shown that ASF/SF2 overexpression preferentially increases usage of the proximal splice site (15) and gives the same effect as IGF-1. SRPK1 has been shown specifically to phosphorylate 12 serines of the RS domain in ASF/SF2 (31), and SRPK2 has been involved in the localization of ASF/SF2 within the nucleus. Thus, in this report, we have investigated the link between the splicing machinery and IGF-1 signaling.
###end p 57
###begin p 58
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1214 1216 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 2479 2481 2479 2481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 2504 2509 2504 2509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 2654 2656 2654 2656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
We have shown that the IGF-1-mediated increase in VEGF isoforms using the proximal splice site is inhibited by blocking PKC and SRPK1/2, and that this can be overcome by the use of a PKC inhibitor or mimicked by a PKC agonist or overexpression of SRPK1. This firmly suggests that this kinase cascade is involved in splice site selection in the VEGF gene. We have used RT-PCR, ELISA, and Western blotting to investigate VEGF splicing. VEGF isoform mRNA expression depends on transcription, splicing, and degradation of mRNA, and protein expression additionally depends upon translational rate and degradation rate. The finding that the mRNA and protein isoforms are both altered in a similar way by each intervention suggests that this is an mRNA switch, at least in part. As the mRNAs are generated by alternative splicing it is unlikely that differential isoform production is due to differential transcription, as both isoforms are transcribed from the same promoter region. However, VEGF has been shown to have two alternate transcription start sites. Although there is no evidence to date to show that these are differentially used for the different exon 8 isoforms, they do confer different exon 7 inclusion (32). If alternate transcription start sites are used, the splicing machinery would still need to be different in order for the transcription complex to recognize the different exon 8 splice sites. It is possible that these two different isoform families are differentially degraded, and that IGF mediates a decrease in degradation of mRNA encoding the proximal splice site. This is a possibility that we have not as yet excluded. However, the finding that ASF/SF2, a known splicing factor, requires the presence of a specific short sequence in the polypyrimidine tract upstream of the proximal splice site and that ASF/SF2 is induced to nuclear localization by SRPK1 activation and IGF-1 activation strongly suggest that this is a splicing mechanism rather than a degradation mechanism. We have shown that ASF/SF2 requires this sequence, which contains both a U2AF65 and consensus ASF/SF2 sequence, for binding to the VEGF pre-mRNA, but does not demonstrate that this is the sequence it binds to. ASF/SF2 binding to a region upstream of a splice site is generally considered a splicing repressor. There is evidence that SR proteins can interact with sequences upstream of the splice site that act as intronic splicing enhancer or silencer regions (reviewed in Ref. 33); for instance in the FGFR2 gene mutations in 50% of the sequential 6 nucleotide sequences in the intronic region upstream of the splice site resulted in altered splicing (34). However, an alternative explanation is that ASF/SF2 requires the U2AF65 consensus sequence adjacent to exon 8a to be present in order for it to bind to consensus sequences downstream and repress distal splice site selection, and hence when mutated or deleted DSS repression is lifted resulting in preferential proximal splice site selection. More research is required to pinpoint the exact mechanism of splicing regulation by ASF/SF2.
###end p 58
###begin p 59
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 265 271 <span type="species:ncbi:9986">rabbit</span>
###xml 352 357 <span type="species:ncbi:9606">human</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
It is still not clear if the IGF-1 system plays a direct role in the growth of new blood vessels. However, there are increasing examples that IGF-1 indirectly increases angiogenesis by up-regulation of VEGF (22, 25, 35). Moreover, IGF-1 induces angiogenesis in the rabbit cornea (36) and stimulates migration, proliferation (37), and tube formation of human endothelial cells (38). IGF-1 is also widely implicated in pathological angiogenesis. Expression of IGF-1 was increased in the vitreous of patients with diabetic retinopathy (39). There is a positive correlation between elevated VEGF-A and IGF-1 in different types of cancers such as colorectal cancer (40), breast cancer (41), and head and neck squamous cell carcinomas (25).
###end p 59
###begin p 60
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRS1</italic>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 219 228 <span type="species:ncbi:10090">nude mice</span>
###xml 349 358 <span type="species:ncbi:10090">nude mice</span>
Moreover, the SFRS1 gene, encoding ASF/SF2, fulfills the criteria of a proto-oncogene (42). Overexpression of ASF/SF2 in immortalized rodent fibroblasts resulted in formation of high-grade sarcomas after injection into nude mice (43). Knock-down of ASF/SF2 in lung carcinoma, which has high expression of that molecule, inhibited tumor formation in nude mice (43).
###end p 60
###begin p 61
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">&#8211;</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 915 917 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 1080 1082 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 1311 1313 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 1543 1546 1543 1546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 1662 1664 1662 1664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1666 1668 1666 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1670 1672 1670 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 1842 1845 1842 1845 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 1862 1864 1862 1864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1212 1217 <span type="species:ncbi:9606">human</span>
###xml 1245 1253 <span type="species:ncbi:9606">patients</span>
There are increasing examples that manipulation of the splicing machinery can be used as new therapeutic targets (44). Small molecules that can target splicing factors and kinases involved in splicing are promising candidates for drugs (17, 45-47). Alternatively, the use of antisense oligonucleotides such as morpholinos, which can bind to the specific splice sites to modulate aberrant splicing has been investigated (48, 49). SRPK1 seems to be a relatively new target for future cancer therapies but is receiving more attention recently as higher expression of SRPK1 has been observed in breast and colonic tumors, and its increased expression is associated with the grade of a tumor (50). Moreover, it has been shown that known anticancer drugs such as gemcitabine and cisplatin increase cell apoptosis with a much stronger effect when phosphorylation of SR proteins was inhibited by using siRNA against SRPK1 (51). SRPK2 is able to bind and phosphorylate acinus, an SR protein, and moves it from nuclear speckles to the nucleoplasm, resulting in the activation of cyclin A1 (52). Moreover, overexpression of acinus or SRPK2 increased leukemia cell proliferation. SRPK2 and acinus were also overexpressed in human acute myelogenous leukemia patients and correlate with elevated cyclin A1 expression levels (52). These two kinases are able to phosphorylate the splicing factor, ASF/SF2 and all these components are involved in the choice of the PSS in VEGF. The inhibitor of SRPK1/2 kinase, SRPIN340 prevents the down-regulation of the VEGFxxxb isoforms. Moreover, SRPK1 and SRPK2 are known to phosphorylate the ASF/SF2 splicing factor with high specificity (21, 31, 53). These results indicate that an overactivity of SRPK1 can cause phosphorylation of ASF/SF2. However, SRPKs have other targets, including those known to up-regulate VEGFxxxb such as SRp55 (15), and the contribution of SRp55 phosphorylation to IGF-mediated effects (perhaps by inhibiting its binding to the distal splice enhancer region) cannot be ruled out. It thus appears likely that SRPK1-mediated phosphorylation of ASF/SF2 could support an activation of the PSS and increased production of pro-angiogenic isoforms.
###end p 61
###begin p 62
###xml 462 465 462 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 716 719 716 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
The overexpression findings, however, suggest that whereas SRPKs are necessary, they are not sufficient for proximal splice site selection. Thus these findings indicate that SRPK1 inhibitors may be potentially anti-angiogenic, and to that end we set out to investigate this in a model of angiogenesis in the eye. A single dose of SRPIN340 resulted in significant inhibition of angiogenesis and increased normal vascularization. Whereas, we have not measured VEGF165b levels in these eyes, there is a discrepancy between total and exon 8a-containing isoforms that is most likely a result of altered splicing. The angiogenesis is known to be mediated by pro-angiogenic VEGF and can be inhibited by anti-angiogenic VEGF165b (18); thus, allowing us to draw a parallel between anti-angiogenic splice forms and inhibition of splice factors that cause pro-angiogenic splicing in the same retinal angiogenesis model. These data suggest that anti-SRPK1 inhibitors may be useful anti-angiogenic agents, suggesting a use in cancer as well as diabetic retinopathy or age-related macular degeneration.
###end p 62
###begin p 63
This work was supported by the British Heart Foundation (FS/04/09 and BS/06/005), the Wellcome Trust (79633), a University of West of England Bristol PhD Studentship, the Richard Bright VEGF Research Trust, Fight for Sight, Cancer Research UK (C11392/A10484), and the Skin Cancer Research Fund.
###end p 63
###begin p 64
###xml 28 32 28 32 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G1">VEGF</term>
###xml 32 66 32 66 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="65">vascular endothelial growth factor</p>
###xml 32 66 32 66 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="65">vascular endothelial growth factor</p></def>
###xml 28 66 28 66 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G1">VEGF</term><def><p textid="65">vascular endothelial growth factor</p></def></def-item>
###xml 66 71 66 71 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G2">IGF-1</term>
###xml 71 97 71 97 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="66">insulin-like growth factor</p>
###xml 71 97 71 97 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="66">insulin-like growth factor</p></def>
###xml 66 97 66 97 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G2">IGF-1</term><def><p textid="66">insulin-like growth factor</p></def></def-item>
###xml 97 99 97 99 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G3">nt</term>
###xml 99 109 99 109 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="67">nucleotide</p>
###xml 99 109 99 109 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="67">nucleotide</p></def>
###xml 97 109 97 109 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G3">nt</term><def><p textid="67">nucleotide</p></def></def-item>
###xml 109 112 109 112 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G4">PBS</term>
###xml 112 137 112 137 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="68">phosphate-buffered saline</p>
###xml 112 137 112 137 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="68">phosphate-buffered saline</p></def>
###xml 109 137 109 137 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G4">PBS</term><def><p textid="68">phosphate-buffered saline</p></def></def-item>
###xml 137 140 137 140 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G5">PKC</term>
###xml 140 156 140 156 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="69">protein kinase C</p>
###xml 140 156 140 156 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="69">protein kinase C</p></def>
###xml 137 156 137 156 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G5">PKC</term><def><p textid="69">protein kinase C</p></def></def-item>
###xml 156 161 156 161 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G6">ELISA</term>
###xml 161 194 161 194 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="70">enzyme-linked immunosorbent assay</p>
###xml 161 194 161 194 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="70">enzyme-linked immunosorbent assay</p></def>
###xml 156 194 156 194 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G6">ELISA</term><def><p textid="70">enzyme-linked immunosorbent assay</p></def></def-item>
###xml 194 197 194 197 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G7">MBP</term>
###xml 197 220 197 220 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="71">maltose-binding protein</p>
###xml 197 220 197 220 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="71">maltose-binding protein</p></def>
###xml 194 220 194 220 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G7">MBP</term><def><p textid="71">maltose-binding protein</p></def></def-item>
###xml 220 223 220 223 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G8">PSS</term>
###xml 223 253 223 253 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="72">proximal splice site selection</p>
###xml 223 253 223 253 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="72">proximal splice site selection</p></def>
###xml 220 253 220 253 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G8">PSS</term><def><p textid="72">proximal splice site selection</p></def></def-item>
###xml 253 256 253 256 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G9">OIR</term>
###xml 256 282 256 282 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="73">oxygen-induced retinopathy</p>
###xml 256 282 256 282 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="73">oxygen-induced retinopathy</p></def>
###xml 253 282 253 282 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G9">OIR</term><def><p textid="73">oxygen-induced retinopathy</p></def></def-item>
###xml 282 285 282 285 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G10">UTR</term>
###xml 285 304 285 304 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="74">untranslated region</p>
###xml 285 304 285 304 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="74">untranslated region</p></def>
###xml 282 304 282 304 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G10">UTR</term><def><p textid="74">untranslated region</p></def></def-item>
###xml 304 307 304 307 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G11">ITS</term>
###xml 307 335 307 335 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="75">insulin transferrin selenium</p>
###xml 307 335 307 335 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="75">insulin transferrin selenium</p></def>
###xml 304 335 304 335 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G11">ITS</term><def><p textid="75">insulin transferrin selenium</p></def></def-item>
###xml 335 338 335 338 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G12">PMA</term>
###xml 338 363 338 363 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="76">phorbol myristate acetate</p>
###xml 338 363 338 363 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="76">phorbol myristate acetate</p></def>
###xml 335 363 335 363 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G12">PMA</term><def><p textid="76">phorbol myristate acetate</p></def></def-item>
###xml 363 366 363 366 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G13">HEK</term>
###xml 366 389 366 389 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="77">human embryonic kidney.</p>
###xml 366 389 366 389 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="77">human embryonic kidney.</p></def>
###xml 363 389 363 389 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G13">HEK</term><def><p textid="77">human embryonic kidney.</p></def></def-item>
###xml 28 389 28 389 <def-list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><def-item><term id="G1">VEGF</term><def><p textid="65">vascular endothelial growth factor</p></def></def-item><def-item><term id="G2">IGF-1</term><def><p textid="66">insulin-like growth factor</p></def></def-item><def-item><term id="G3">nt</term><def><p textid="67">nucleotide</p></def></def-item><def-item><term id="G4">PBS</term><def><p textid="68">phosphate-buffered saline</p></def></def-item><def-item><term id="G5">PKC</term><def><p textid="69">protein kinase C</p></def></def-item><def-item><term id="G6">ELISA</term><def><p textid="70">enzyme-linked immunosorbent assay</p></def></def-item><def-item><term id="G7">MBP</term><def><p textid="71">maltose-binding protein</p></def></def-item><def-item><term id="G8">PSS</term><def><p textid="72">proximal splice site selection</p></def></def-item><def-item><term id="G9">OIR</term><def><p textid="73">oxygen-induced retinopathy</p></def></def-item><def-item><term id="G10">UTR</term><def><p textid="74">untranslated region</p></def></def-item><def-item><term id="G11">ITS</term><def><p textid="75">insulin transferrin selenium</p></def></def-item><def-item><term id="G12">PMA</term><def><p textid="76">phorbol myristate acetate</p></def></def-item><def-item><term id="G13">HEK</term><def><p textid="77">human embryonic kidney.</p></def></def-item></def-list>
The abbreviations used are: VEGFvascular endothelial growth factorIGF-1insulin-like growth factorntnucleotidePBSphosphate-buffered salinePKCprotein kinase CELISAenzyme-linked immunosorbent assayMBPmaltose-binding proteinPSSproximal splice site selectionOIRoxygen-induced retinopathyUTRuntranslated regionITSinsulin transferrin seleniumPMAphorbol myristate acetateHEKhuman embryonic kidney.
###end p 64
###begin p 65
vascular endothelial growth factor
###end p 65
###begin p 66
insulin-like growth factor
###end p 66
###begin p 67
nucleotide
###end p 67
###begin p 68
phosphate-buffered saline
###end p 68
###begin p 69
protein kinase C
###end p 69
###begin p 70
enzyme-linked immunosorbent assay
###end p 70
###begin p 71
maltose-binding protein
###end p 71
###begin p 72
proximal splice site selection
###end p 72
###begin p 73
oxygen-induced retinopathy
###end p 73
###begin p 74
untranslated region
###end p 74
###begin p 75
insulin transferrin selenium
###end p 75
###begin p 76
phorbol myristate acetate
###end p 76
###begin p 77
###xml 0 5 <span type="species:ncbi:9606">human</span>
human embryonic kidney.
###end p 77
###begin title 78
REFERENCES
###end title 78

